Yaz›flma Adresi / Address for Correspondence



Yüklə 369,37 Kb.
Pdf görüntüsü
səhifə6/6
tarix15.03.2017
ölçüsü369,37 Kb.
#11433
1   2   3   4   5   6

[CrossRef]

68.  Omata M, Kanda T, Yu ML, et al. APASL consensus statements 

and management algorithms for hepatitis C virus infection. He-

patol Int. 2012; 6(2): 409-5. 

[CrossRef]

69.  Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b the-

rapy in acute hepatitis C: impact of onset of therapy on sustai-

ned virologic response. Gastroenterology. 2006; 130(3): 632-8. 



[CrossRef]

70.  European Association for the Study of the Liver. EASL Clinical 

Practice Guidelines: management of hepatitis C virus infection. 

J Hepatol. 2011; 55(2): 245-64. 

[CrossRef]

71.  Boesecke C, Wedemeyer H, Rockstroh JK. Diagnosis and treat-

ment of acute hepatitis C virus infection. Infect Dis Clin North 

Am. 2012; 26(4): 995-1010. 

[CrossRef]

72.  Ohfuji S, Fukushima W, Tanaka T, et al. Coffee consumption and 

reduced risk of hepatocellular carcinoma among patients with 

chronic type C liver disease: A case-control study. Hepatology 



Res. 2006; 36(3): 201-8. 

[CrossRef]

73.  Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic res-

ponse is durable in patients with chronic hepatitis C treated with 

peginterferon alfa-2a and ribavirin. Gastroenterology. 2010; 

139(5): 1593-601. 

[CrossRef]

74.  McCaughan GW, Omata M, Amarapurkar D, et al. Asian Pacific 

Association for the Study of the Liver consensus statements on 

the diagnosis, management and treatment of hepatitis C virus in-

fection. J Gastroenterol Hepatol. 2007; 22(5): 615-33. 

[CrossRef]

75.  Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a 

plus ribavirin for chronic hepatitis C virus infection. N Engl J 

Med. 2002; 347(13): 975-82. 

[CrossRef]

76.  Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-

2b plus ribavirin compared with interferon alfa-2b plus ribavirin for 

initial treatment of chronic hepatitis C: a randomised trial. Lancet

2001; 358(9286): 958-65. 

[CrossRef]

77.  Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment 

outcome in patients with chronic hepatitis C: significance of ba-

seline parameters and viral dynamics during therapy. Hepato-



logy. 2003; 37(3): 600-9. 

[CrossRef]

78.  Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Alb-

recht J. Early virologic response to treatment with peginterferon 

alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepa-



tology. 2003; 38(3): 645-52. 

[CrossRef]

79.  Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for 

previously untreated chronic hepatitis C virus infection. N Engl 

J Med. 2011; 364(25): 2405-16. 

[CrossRef]

80.  Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender 

Reddy K, Harrison SA, et al. Anemia during treatment with pe-

ginterferon alfa-2b/ribavirin and boceprevir: analysis from the 

serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology

2013; 57(3): 974-84. 



[CrossRef]

81.  ACIP Adult Immunization Work Group, Bridges CB, Woods L, 

Coyne-Beasley T; Centers for Disease Control and Prevention 

(CDC). Advisory Committee on Immunization Practices (ACIP) 

recommended immunization schedule for adults aged 19 years 

and older-United States, 2013. MMWR Surveill Summ. 2013; 

62(Suppl. 1):9-19.

82.  Shantha S, Thyagarajan SP, Premavathy RK, et al. Correlation of 

autoimmune reactivity with hepatitis B and C virus (HBV and 

HCV) infection in histologically proven chronic liver diseases. In-



dian J Med Microbiol. 2002; 20(1): 12-5.

83.  Naing C, Mak JW, Ahmed SI, Maung M. Relationship between he-

patitis C virus infection and type 2 diabetes mellitus: meta-analy-

sis. World J Gastroenterol. 2012; 18(14): 1642-51. 



[CrossRef]

84.  Lin CY, Sheen IS, Chen JY, et al. Various predictors of sustained 

virologic response in different age groups of patients with genoty-

pe-1 chronic hepatitis C. J Clin Gastroenterol. 2013; 47(9): 794-9. 



[CrossRef]

85.  Holmberg SD, Lu M, Rupp LB, et al. Noninvasive serum fibro-

sis markers for screening and staging chronic hepatitis C virus 

patients in a large US cohort. Clin Infect Dis. 2013; 57(2): 240-6. 



[CrossRef]

86.  Attallah AM, El-Far M, Omran MM, Farid K, Albannan MS, El-

Dosoky I. Noninvasive diagnosis of liver fibrosis and cirrhosis in 

chronic hepatitis C patients. J Clin Lab Anal. 2013; 27(2): 121-9. 



[CrossRef]

87.  Sporea I, Sirli R, Deleanu A, et al. Comparison of the liver stiff-

ness measurement by transient elastography with the liver bi-

opsy. World J Gastroenterol. 2008; 14(42): 6513-7. 



[CrossRef]

88.  Goldberg E, Chopra S. Cirrhosis in adults: overview of complica-

tions, general management, and prognosis [İnternet]. Waltham, 

MA: UpToDate, Inc.  [erişim 2 Haziran 2014]. http://www.uptoda-

te.com/contents/cirrhosis-in-adults-overview-of-complications-

general-management-and-prognosis?source=search_result&se

arch=compensated+cirrhosis&selectedTitle=1~150 

89.  Pearlman BL, Ehleben C. Hepatitis C genotype 1 virus with low viral 

load and rapid virologic response to peginterferon/ribavirin obvia-

tes a protease inhibitor. Hepatology. 2014; 59(1): 71-7. 



[CrossRef]

90.  Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-

analysis: IL28B polymorphisms predict sustained viral response 

in HCV patients treated with pegylated interferon-alpha and ri-

bavirin. Aliment Pharmacol Ther. 2012; 36(2): 91-103. 

[CrossRef]

91.  Mangia A, Mottola L, Santoro R. Interleukin 28B polymorphisms 

as predictor of response in hepatitis C virus genotype 2 and 3 

infected patients. World J Gastroenterol. 2013; 19(47): 8924-8. 



[CrossRef]

92.  Feld JJ. Treatment indication and response to standard of care 

with peginterferon and ribavirin in acute and chronic HCV in-

fection. Best Pract Res Clin Gastroenterol. 2012; 26(4): 429-44. 



[CrossRef]

93.  Niederau C, Mauss S, Boker K, et al. Noncompliance with guide-

lines for the treatment of hepatitis C is frequent in daily practice.  

Eur J Gastroenterol Hepatol. 2014; 26(1): 65-73. 

[CrossRef]

94.  Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously 

treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 

364(13): 1207-17. 



[CrossRef]

95.  Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of 

HCV infection. N Engl J Med. 2011; 364(25): 2417-28. 

[CrossRef]

96.  Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B 

and spontaneous clearance of hepatitis C virus. Nature. 2009; 

461(7265): 798-801. 



[CrossRef]

97.  Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B 

predicts hepatitis C treatment-induced viral clearance. Nature

2009; 461(7262): 399-401. 



[CrossRef]

98.  Recommendations for Testing Managing, and Treating Hepa-

titis C: Initial Treatment of HCV Infection [İnternet]. Alexandria 

and Arlington, VA: American Association for the Study of Liver 

Diseases (AASLD) and Infectious Diseases Society of America 

Aygen B et al. Kronik Hepatit C Virusu İnfeksiyonunun Yönetimi          37


(IDSA) [erişim 26 Mart 2014]. http://www.hcvguidelines.org/full-

report/initial-treatment-hcv-infection.

99.  Martell M, Esteban JI, Quer J, et al. Hepatitis C virus (HCV) cir-

culates as a population of different but closely related genomes: 

quasispecies nature of HCV genome distribution. J Virol. 1992; 

66(5): 3225-9. 

100. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting 

antiviral agents: the best interferon-free combinations. Liver Int

2014; 34(Suppl. 1): 69-78. 

[CrossRef]

101. Vermehren J, Sarrazin C. The role of resistance in HCV treat-

ment.  Best Pract Res Clin Gastroenterol. 2012; 26(4): 487-503. 

[CrossRef]

102. McCown MF, Rajyaguru S, Kular S, Cammack N, Najera I. GT-

1a or GT-1b subtype-specific resistance profiles for hepatitis C 

virus inhibitors telaprevir and HCV-796. Antimicrob Agents Che-



mother. 2009; 53(5): 2129-32. 

[CrossRef]

103. Sayan M. Proteaz inhibitörlerinde Türkiye direnç analizi [DVD]. 



In: Kronik Hepatit C: Yeni Gelişmeler ve Türkiye Deneyimi (21 

Eylül 2013, İstanbul) Atölye Çalışması. İstanbul: Türk Klinik Mik-

robiyoloji ve İnfeksiyon Hastalıkları Derneği, 2013.

104. De Meyer S, Thys K, Dierynck I, Ghys A, Aerssens J, Picchio G. 

Deep sequencing screening for telaprevir-resistant viral variants 

in previous null responders fails to identify those patients at risk 

of failing telaprevir plus peginterferon/ribavirin therapy. J Hepa-

tol. 2012; 56: S465. 

[CrossRef]

105. Andonov A, Kadkhoda K, Osiowy C, Kaita K. Pretreatment resis-

tance to hepatitis C virus protease inhibitors boceprevir/telap-

revir in hepatitis C virus subgenotype 1a-infected patients from 

Manitoba. Can J Gastroenterol. 2013; 27(7): 414-6.

106. Hoffmann L, Ramos JA, Souza EV, et al. Dynamics of resistan-

ce mutations to NS3 protease inhibitors in a cohort of Brazilian 

patients chronically infected with hepatitis C virus (genotype 1) 

treated with pegylated interferon and ribavirin: a prospective 

longitudinal study. Virol J. 2013; 10: 57. 



[CrossRef]

107. Palanisamy N, Danielsson A, Kokkula C, et al. Implications of ba-

seline polymorphisms for potential resistance to NS3 protease 

inhibitors in hepatitis C virus genotypes 1a, 2b and 3a. Antiviral 



Res. 2013; 99(1): 12-7. 

[CrossRef]

108. Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically 

targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimic-

rob Chemother. 2010; 65(2): 202-12. 

[CrossRef]

109. Kieffer TL, Sarrazin C, Miller JSet al. Telaprevir and pegylated 

interferon-alpha-2a inhibit wild-type and resistant genotype 1 he-

patitis C virus replication in patients. Hepatology. 2007; 46(3): 631-9. 



[CrossRef]

110. Kieffer TL, De Meyer S, Bartels DJ, et al. Hepatitis C viral evolu-

tion in genotype 1 treatment-naive and treatment-experienced 

patients receiving telaprevir-based therapy in clinical trials. PloS 



One. 2012; 7(4): e34372. 

[CrossRef]

111. Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict 

response of patients with hepatitis C virus infection to bocepre-

vir. Gastroenterology. 2012; 143(3): 608-18 e1-5.

112. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B 

polymorphism improves viral kinetics and is the strongest pret-

reatment predictor of sustained virologic response in genotype 

1 hepatitis C virus. Gastroenterology. 2010; 139(1): 120-9 e18. 

113. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alp-

ha2a and ribavirin combination therapy in chronic hepatitis C: a 

randomized study of treatment duration and ribavirin dose.  Ann 

Intern Med. 2004; 140(5): 346-55. 

[CrossRef]

114. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of 

HCV genotype 1 patients responding to 24 weeks peginterferon 

alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006; 43(5): 954-60. 



[CrossRef]

 

115. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and 



ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with 

rapid virological response. Gastroenterology. 2008; 135(2): 451-8. 



[CrossRef]

 

116. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment 



with peginterferon alfa-2b plus ribavirin in patients with chronic 

hepatitis C infected with genotype 1 and low pretreatment vire-

mia. J Hepatol. 2006; 44(1): 97-103. 

[CrossRef]

117. Mangia A, Minerva N, Bacca D, et al. Individualized treatment 

duration for hepatitis C genotype 1 patients: a randomized cont-

rolled trial. Hepatology. 2008; 47(1): 43-50. 



[CrossRef]

118. Moreno C, Deltenre P, Pawlotsky JM, Henrion J, Adler M, Mathu-

rin P. Shortened treatment duration in treatment-naive genotype 

1 HCV patients with rapid virological response: a meta-analysis. 



J Hepatol. 2010; 52(1): 25-31. 

[CrossRef]

119. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sus-

tained virologic response in hepatitis B and C. J Hepatol. 2008; 

49(4): 634-51. 



[CrossRef]

120. Wartelle-Bladou C, Le Folgoc G, Bourliere M, Lecomte L. Hepati-

tis C therapy in non-genotype 1 patients: the near future. J Viral 

Hepat. 2012; 19(8): 525-36. 

[CrossRef]

121. Sung H, Chang M, Saab S. Management of hepatitis C anti-

viral therapy adverse effects.  Curr Hepat Rep. 2011; 10(1): 

33-40. 


[CrossRef]

122. Friedrich-Rust M, Theobald J, Zeuzem S, Bojunga J. Thyroid 

function and changes in ultrasound morphology during antivi-

ral therapy with pegylated interferon and ribavirin in patients 

with chronic hepatitis C. J Viral Hepat. 2009; 16(3): 168-77. 

[CrossRef]

123. Chang CH, Chen KY, Lai MY, Chan KA. Meta-analysis: ribavirin-

induced haemolytic anaemia in patients with chronic hepatitis 

C. Aliment Pharmacol Ther. 2002; 16(9): 1623-32. 



[CrossRef]

124. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previo-

usly treated chronic HCV infection. N Engl J Med. 2010; 362(14): 

1292-303. 



[CrossRef]

125. Roujeau JC, Mockenhaupt M, Tahan SR, et al. Telaprevir-related 

dermatitis. JAMA Dermatol. 2013; 149(2): 152-8. 

[CrossRef]

126. Hofmann WP, Chung TL, Osbahr C, et al. Impact of ribavirin on 

HCV replicon RNA decline during treatment with interferon-alp-

ha and the protease inhibitors boceprevir or telaprevir. Antivir 



Ther. 2011; 16(5): 695-704. 

127. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untre-

ated chronic HCV genotype 1 infection. N Engl J Med. 2011; 

364(13): 1195-206. 



[CrossRef]

128. Koff RS. Review article: the efficacy and safety of sofosbuvir, a 

novel, oral nucleotide NS5B polymerase inhibitor, in the treat-

ment of chronic hepatitis C virus infection. Aliment Pharmacol 



Ther. 2014; 39(5): 478-87. 

[CrossRef]

129. Dienstag JL. Chronic viral hepatitis. In: Mandell GL, Bennett JE, 

Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and 

Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Churc-

hill Livingstone Elsevier, 2010: 1593-617. 



[CrossRef]

130. Kee KM, Lee CM, Wang JH, et al. Thyroid dysfunction in patients 

with chronic hepatitis C receiving a combined therapy of interfe-

ron and ribavirin: incidence, associated factors and prognosis. 



Gastroenterol Hepatol. 2006; 21(1 Pt. 2): 319-26. 

[CrossRef]

131. Aygen B. Kronik hepatit C’de tedavi ve izlem. In: Köksal İ, Leb-

lebicioğlu H, eds. Kronik Hepatitlerin Tedavisinde Güncel Yakla-

şımlar. Ankara: Bilimsel Tıp Yayınevi, 2007: 173-83.

132. Recommendations for Testing Managing, and Treating Hepatitis 

C: Retreatment of Persons In Whom Prior Therapy Has Failed 

[İnternet]. Alexandria and Arlington, VA: American Association 

for the Study of Liver Diseases (AASLD) and Infectious Diseases 

Society of America (IDSA) [erişim 18 Şubat 2014]. http://www.

38 

Klimik Dergisi 2014; 27(Özel Sayı 1): 19-39


hcvguidelines.org/full-report/retreatment-persons-whom-prior-

therapy-has-failed.

133. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, mana-

gement, and treatment of hepatitis C. Hepatology. 2004; 39(4): 

1147-71. 

[CrossRef]

134. Corey KE, Servoss JC, Casson DR, et al. Pilot study of postex-

posure prophylaxis for hepatitis C virus in healthcare workers. 

Infect Control Hosp Epidemiol. 2009; 30(10): 1000-5. 

[CrossRef]

135. Aygen B. Yoğun bakım biriminde çalışanlarda kan ve vücut sıvı-

ları ile bulaşan infeksiyonlardan korunma. In: Akalın H, Aygen B, 

Yalçın AN, eds. İnfeksiyon Hastalıklarında Güncel Durum. İstan-

bul: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği 

Yayınları, 2009: 141-51.

136. Deuffic-Burban S, Abiteboul D, Lot F, Branger M, Bouvet E, Yaz-

danpanah Y. Costs and cost-effectiveness of different follow-up 

schedules for detection of occupational hepatitis C virus infecti-

on. Gut. 2009; 58(1): 105-10. 



[CrossRef]

137. Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C. 

Sensitivity and specificity of third-generation hepatitis C virus 

antibody detection assays: an analysis of the literature. J Viral 



Hepat. 2001; 8(2): 87-95. 

[CrossRef]

138. Lavanchy D, Steinmann J, Moritz A, Frei PC. Evaluation of a new 

automated third-generation anti-HCV enzyme immunoassay. 

Clin Lab Anal. 1996; 10(5): 269-76. 

3.0.CO;2-3">[CrossRef]

139. Lefrere JJ, Roudot-Thoraval F, Lunel F, et al. Expertise of French la-

boratories in detection, genotyping, and quantification of hepatitis 

C virus RNA in serum. J Clin Microbiol. 2004; 42(5): 2027-30. 

[Cross-

Ref]

140. Updated U.S. Public Health Service Guidelines for the Mana-

gement of Occupational Exposures to HBV, HCV, and HIV and 

Recommendations for Postexposure Prophylaxis. MMWR Re-



comm Rep. 2001; 50(RR-11): 1-52.

141. Puro V, De Carli G, Cicalini S, et al. European recommendations 

for the management of healthcare workers occupationally expo-

sed to hepatitis B virus and hepatitis C virus. Euro Surveill. 2005; 

10(10): 260-4.

142. Deuffic-Burban S, Delarocque-Astagneau E, Abiteboul D, Bouvet 

E, Yazdanpanah Y. Blood-borne viruses in health care workers: 

prevention and management. J Clin Virol. 2011; 52(1): 4-10. 



[CrossRef]

143. Ramsay ME. Guidance on the investigation and management of 

occupational exposure to hepatitis C. PHLS Advisory Committee 

on Blood Borne Viruses. Commun Dis Public Health. 1999; 2(4): 

258-62. 

144. Charles PG, Angus PW, Sasadeusz JJ, Grayson ML. Manage-

ment of healthcare workers after occupational exposure to he-

patitis C virus. Med J Aust. 2003; 179(3): 153-7.



Aygen B et al. Kronik Hepatit C Virusu İnfeksiyonunun Yönetimi          39

Yüklə 369,37 Kb.

Dostları ilə paylaş:
1   2   3   4   5   6




Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©azkurs.org 2024
rəhbərliyinə müraciət

gir | qeydiyyatdan keç
    Ana səhifə


yükləyin